Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy

被引：28

作者：

Alberto Henriquez-Hernandez, Luis ^{[1
,3
]}

Murias-Rosales, Adolfo ^{[2
,3
]}

Gonzalez-Hernandez, Ana ^{[3
,4
]}

Cabrera de Leon, Antonio ^{[3
,4
]}

Diaz-Chico, Nicolas ^{[3
,5
]}

Fernandez-Perez, Leandro ^{[1
,3
]}

机构：

[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain

[2] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain

[3] ICIC, Madrid, Spain

[4] Hosp La Candelaria, Hosp Univ La Candelaria, Res Unit, Santa Cruz De Tenerife 38010, Spain

[5] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain

来源：

CANCER EPIDEMIOLOGY | 2010年 / 34卷 / 05期

关键词：

Breast cancer; Neoadjuvant chemotherapy; Toxicity; Adverse reaction; Polymorphism; MTHFR; p53; ACUTE LYMPHOBLASTIC-LEUKEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE C677T; THYMIDYLATE SYNTHASE; OVARIAN-CANCER; TOXICITY; PHARMACOGENOMICS; THERAPY; RESISTANCE; VARIANTS; RISK;

D O I：

10.1016/j.canep.2010.06.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Results Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p = 0.018) and 7.0 (95% confidence interval, 1.2-40.5; p = 0.029), respectively). Conclusion We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：634 / 638

页数：5

共 45 条

[21] Role of the MTHFR polymorphisms in cancer risk modification and treatment
Kim, Young-In
[J]. FUTURE ONCOLOGY, 2009, 5 (04) : 523 - 542
[22] P53 MUTATIONS INCREASE RESISTANCE TO IONIZING-RADIATION
LEE, JM
BERNSTEIN, A
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5742 - 5746
[23] ATP binding cassette transporters and drug resistance in breast cancer
Leonessa, F
Clarke, R
[J]. ENDOCRINE-RELATED CANCER, 2003, 10 (01) : 43 - 73
[24] P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO
LOWE, SW
BODIS, S
MCCLATCHEY, A
REMINGTON, L
RULEY, HE
FISHER, DE
HOUSMAN, DE
JACKS, T
[J]. SCIENCE, 1994, 266 (5186) : 807 - 810
[25] Pharmacogenomics: from bedside to clinical practice
Marsh, S
McLeod, HL
[J]. HUMAN MOLECULAR GENETICS, 2006, 15 : R89 - R93
[26] Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
Marsh, Sharon
Paul, Jim
King, Cristi R.
Gifford, Gillian
McLeod, Howard L.
Brown, Robert
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4528 - 4535
[27] Impact of pharmacogenomics on clinical practice in oncology
Marsh, Sharon
[J]. MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (02) : 79 - 82
[28] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[29] 2-6
[30] Nilsson G, 1999, CANCER RES, V59, P3180

← 1 2 3 4 5 →